{"DataElement":{"publicId":"2187968","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Skin Telangiectasia Grade","preferredDefinition":"in CTC category Dermatology/Skin, assessment of the severity of a telangiectasia adverse event using a graded scale.","longName":"CTC_AE_SKIN_TELAN_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2198310","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Skin Telangiectasia","preferredDefinition":"information related to the CTC adverse event of skin telangiectasia.","longName":"CTC_AE_SKIN_TELANG","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207565","version":"1","preferredName":"Skin Telangiectasia","preferredDefinition":"1. An organ and the enveloping membrane of the body; includes, in addition to the epidermis and dermis, all of the derivatives of the epidermis, e.g., hairs, nails, sudoriferous and sebaceous glands, and mammary glands. Subdivisions of the skin surround various body parts; as a whole, the skin constitutes the external surface of the body. 2. The rind, capsule, or covering of any body or part.:Permanent dilation of preexisting blood vessels (capillaries, arterioles, venules) creating small focal red lesions, most commonly in the skin or mucous membranes.","longName":"C12470:C28194","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin","conceptCode":"C12470","definition":"An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Telangiectasia","conceptCode":"C28194","definition":"Local dilatation of small vessels resulting in red discoloration of the skin or mucous membranes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-28A3-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF21B628-B838-1CE0-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2187967","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Skin Telangiectasia Grade","preferredDefinition":"in CTC category Dermatology/Skin, assessment of the severity of a telangiectasia adverse event using a graded scale.","longName":"CTC_AE_SKIN_TELAN_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"0","valueDescription":"None at all","ValueMeaning":{"publicId":"2574138","version":"1","preferredName":"None at all","longName":"2574138","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EEA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CLOHNES","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":"8/12/22 added alt VM for Alliance cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1ED58C2-4871-01F5-E034-0003BA12F5E7","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"1","valueDescription":"Mild","ValueMeaning":{"publicId":"2563414","version":"1","preferredName":"Mild","longName":"2563414","preferredDefinition":"Not severe or strong; far from extreme; not serious enough to endanger life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mild","conceptCode":"C70666","definition":"Gentle or temperate in nature or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C4C3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"COOPERM","dateModified":"2008-10-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1ED58C2-4873-01F5-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"Moderate number","ValueMeaning":{"publicId":"2571637","version":"1","preferredName":"Moderate number","longName":"2571637","preferredDefinition":"Moderate number","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E4E2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"SHIDED","dateModified":"2004-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1ED58C2-4876-01F5-E034-0003BA12F5E7","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Many and confluent","ValueMeaning":{"publicId":"2571638","version":"1","preferredName":"Many and confluent","longName":"2571638","preferredDefinition":"Many and confluent","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E4E3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"SHIDED","dateModified":"2004-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1ED58C2-487A-01F5-E034-0003BA12F5E7","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1ED500F-C419-0188-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"REEVESD","dateModified":"2014-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CTC Adverse Event Telangiecta","type":"Preferred Question Text","description":"CTC Adverse Event Telangiectasia Grade","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Telangiectasia Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E1ED402F-56FC-01D6-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}